Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall St set to snap three-day losing streak as stocks reclaim some shine
- Oil settles 1% higher, as US-Iran strikes threaten supplies
- Dell again lifts annual forecasts as AI demand powers record results
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- Uber stock gains 2% as tech giant cuts 3,300 jobs in major restructuring
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Crude Inventory Fell 4.5M Barrels Last Week - EIA
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- TScan cuts 75% of workforce, pivots to solid tumor cell therapy
Vertex (VRTX) PT Raised to $459 at Morgan Stanley
February 11, 2025 7:10 AM ESTMorgan Stanley analyst Terence Flynn raised the price target on Vertex (NASDAQ: VRTX) to $459.00 (from $450.00) while maintaining a Equalweight rating.
The analyst comments "VRTX posted a 4Q beat and first time 2025 Rev/expense guidance bracketed consensus. Looking ahead the focus is on... More
Vertex Pharma (VRTX) Misses Q4 EPS by 4c, Revenues Beat
February 10, 2025 4:04 PM ESTVertex Pharma (NASDAQ: VRTX) reported Q4 EPS of $3.98, $0.04 worse than the analyst estimate of $4.02. Revenue for the quarter came in at $2.91 billion versus the consensus estimate of $2.79 billion.
GUIDANCE:
Vertex Pharma sees FY2025 revenue of $11.75-12 billion, versus the consensus of... More
